Thomas Reilly - Opthea Chief Officer

OPT Stock  USD 3.33  0.00  0.00%   

Executive

Thomas Reilly is Chief Officer of Opthea
Age 52
Address 650 Chapel Street, South Yarra, VIC, Australia, 3141
Phone61 3 9826 0399
Webhttps://opthea.com

Thomas Reilly Latest Insider Activity

Tracking and analyzing the buying and selling activities of Thomas Reilly against Opthea stock is an integral part of due diligence when investing in Opthea. Thomas Reilly insider activity provides valuable insight into whether Opthea is net buyers or sellers over its current business cycle. Note, Opthea insiders must abide by specific rules, including filing SEC forms every time they buy or sell Opthea'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Opthea Management Efficiency

The company has Return on Asset of (0.8343) % which means that on every $100 spent on assets, it lost $0.8343. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (33.8308) %, meaning that it generated no profit with money invested by stockholders. Opthea's management efficiency ratios could be used to measure how well Opthea manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.22 in 2024. Return On Capital Employed is likely to gain to -1.46 in 2024. At this time, Opthea's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 198.2 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39.8 M in 2024.
Opthea has 141.65 M in debt. Opthea has a current ratio of 4.87, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Opthea to invest in growth at high rates of return.

Similar Executives

Showing other executives

EXECUTIVE Age

Lori BeerJPMorgan Chase Co
56
Timothy BrownHP Inc
57
David RozzionHP Inc
N/A
Shesha KrishnapuraIntel
N/A
Andrew WalzChevron Corp
56
Ahmet TezelJohnson Johnson
N/A
Mike ListerJPMorgan Chase Co
N/A
Lisa PearceIntel
N/A
Brett IversenMicrosoft
N/A
Bader AlamoudiJPMorgan Chase Co
N/A
Mary FrancisChevron Corp
60
Bernard McGuinnessThe Coca Cola
58
Takeshi NumotoMicrosoft
53
Alice JollaMicrosoft
58
Francis PearnJPMorgan Chase Co
N/A
Szymon RomikIntel
N/A
Antonio LucioHP Inc
65
Christopher YoungMicrosoft
52
Manuel PrietoThe Coca Cola
57
John PitzerIntel
N/A
Todd LevyChevron Corp
N/A
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. Opthea operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Opthea (OPT) is traded on NASDAQ Exchange in USA. It is located in 650 Chapel Street, South Yarra, VIC, Australia, 3141 and employs 33 people. Opthea is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Opthea Leadership Team

Elected by the shareholders, the Opthea's board of directors comprises two types of representatives: Opthea inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opthea. The board's role is to monitor Opthea's management team and ensure that shareholders' interests are well served. Opthea's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opthea's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Chief Officer
MD MA, Chief Advisor
Sarika Gulhar, Executive Resources
Michael Gerometta, Manufacturing Chemistry
Peter MBA, Chief Officer
Jen Watts, VP Operations
Karen CPA, VP Secretary
Anand Sundaram, Vice Marketing
PharmD MS, Chief Officer
Kenneth Sall, Chief Officer
Dayong Li, Biometrics VP
Mike Campbell, Chief Officer
Ian Leitch, Director Research
James Goding, Independent Consultant
Kevin Bitter, VP Development
MAICD MAICD, CEO MD
MSc BPHARM, Senior Operations
MD MBA, Chief Officer
Daniel MBA, Interim CFO
MS MD, Senior Development
Annie Lee, F Mang
Thomas Reilly, Chief Officer
Fang Li, Senior Affairs

Opthea Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opthea a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Opthea Stock Analysis

When running Opthea's price analysis, check to measure Opthea's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opthea is operating at the current time. Most of Opthea's value examination focuses on studying past and present price action to predict the probability of Opthea's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opthea's price. Additionally, you may evaluate how the addition of Opthea to your portfolios can decrease your overall portfolio volatility.